Table 1.
Impact of baseline characteristics on patient prognosis
| Variable | Total (n=174), n (%) | 5Y DRFS (%) | p-value |
|---|---|---|---|
| Age (yr) | |||
| Median | 46.0±10.1 | - | |
| Range | 23.5-73.1 | - | 0.469 |
| < 40 | 46 (26.4) | 80.1 | |
| ≥ 40 | 128 (73.6) | 86.6 | |
| Histology | |||
| IDC | 154 (88.5) | 85.6 | 0.288 |
| Other | 20 (11.5) | 80.0 | |
| Stage | |||
| I | 44 (25.3) | 88.4 | < 0.001 |
| IIA | 87 (50.0) | 91.9 | |
| IIB | 25 (14.4) | 75.8 | |
| IIIA | 12 (6.9) | 64.8 | |
| IIIB | 0 | NA | |
| IIIC | 6 (3.4) | 33.3 | |
| Nuclear grade | |||
| 1 | 2 (1.1) | 50.0 | 0.144 |
| 2 | 41 (23.6) | 82.7 | |
| 3 | 125 (71.8) | 87.1 | |
| Unknown | 6 (3.4) | 66.7 | |
| Histologic grade | |||
| 1 | 3 (1.7) | 100.0 | 0.606 |
| 2 | 39 (22.4) | 84.5 | |
| 3 | 122 (70.1) | 85.9 | |
| Unknown | 10 (5.7) | 70.0 | |
| p53 IHC | |||
| Positive | 103 (59.0) | 85.4 | 0.151 |
| Negative | 69 (40.0) | 81.2 | |
| Unknown | 2 (1.1) | 50.0 | |
| TP53 mutation | |||
| Wild type | 97 (55.7) | 82.5 | 0.625 |
| Missense | 49 (28.2) | 81.6 | |
| Nonsense/Frameshift/Splicing | 28 (16.1) | 89.3 | |
| TP53 mRNA expression | |||
| Median | 228.52±147.81 | - | 0.593 |
| Range | 32.40-736.09 | - | |
| Low | 87 (50.0) | 81.6 | |
| High | 87 (50.0) | 85.1 | |
| Adjuvant CTx | |||
| CMF | 76 (43.7) | 89.4 | 0.001 |
| Anthracycline | 63 (36.2) | 90.3 | |
| Anthracycline+taxane | 35 (20.1) | 65.5 | |
| Adjuvant RTx | |||
| Yes | 110 (63.2) | 82.5 | 0.109 |
| No | 64 (36.8) | 89.0 |
5Y DRFS, 5-year distant recurrence-free survival; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; CTx, chemotherapy; CMF, cyclophosphamide+methotrexate+5-fluorouracil; RTx, radiotherapy.